A platform technology that generates disease-specific regulatory T cells (Tregs) to reverse autoimmune diseases by suppressing autoimmune attacks without impairing normal immune function.

A lead Navacim drug candidate showing disease modification and hepatoprotection in preclinical models of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, and Autoimmune Hepatitis.